The latest news on the growing cost of conducting clinical trials is becoming a major concern for company sponsors and trial co-operative groups.
Mukhtaer Ahmed outlines how advances in machine-to-machine (M2M) technologies have the potential to transform clinical development programs, including clinical trials.